• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

byJessie WillisandTeddy Guo
November 30, 2022
in Chronic Disease, Endocrinology, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. SGLT2 inhibitors reduced the risk of kidney disease progression by 37% overall, with comparable effects in patients with and without diabetes.

2. SGLT2 inhibitors also reduced the risk of cardiovascular mortality in patients with and without diabetes.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Sodium glucose co-transporter-2 (SGLT2) inhibitors are a class of anti-hyperglycemic drugs which have been shown to have cardiovascular benefitz. Studies have also demonstrated that SGLT2 inhibitors reduce the risk kidney disease progression, but few of these studies evaluated patients without diabetes. This systematic review and meta-analysis analyzed the results from 13 large-scale double-blind trials comparing SGLT2 inhibitors in patients with and without diabetes. Compared to placebo, SGLT2 inhibitors were shown to reduce the risk of kidney disease progression by 37%. This risk reduction was similarly seen in patients with and without diabetes. SGLT2 inhibitors additionally reduced the risk of acute kidney injury and cardiovascular death, irrespective of diabetic status. The risk of adverse effects, such as ketoacidosis and amputation, were shown to be rare and outweighed by the benefits. A limitation of this study includes the lack of participant-level data from some of the included trials. Nevertheless, this study provides strong evidence for the use of SGLT2 inhibitors for reducing the risk of kidney disease progression for both patients with and without diabetes.

Click to read the study in the Lancet

Relevant Reading: SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

In-Depth [systematic review and meta-analysis]: A database search was conducted. Eligible trials included those that assessed SGLT2 inhibitors and were double-blind, placebo-controlled, large-scale (>500 participants in each arm), at least 6 months in duration, and were performed in adults (age ≥ 18 years). The primary outcome was kidney disease progression (defined as a sustained >50% decrease in eGFR, a sustained low eGFR, ESKD, or death from kidney failure). A total of 13 trials (n=90 413) were identified. There were 74 804 (82.7%) participants with diabetes and 15 605 (17.3%) without diabetes. SGLT2 inhibitors reduced the risk of kidney disease progression compared to placebo (RR 0.63, 95% CI 0.58-0.69). This reduction in risk was similar irrespective of diabetes status, primary kidney diagnosis, and baseline eGFR. For secondary outcomes, SGLT2 inhibitors additionally reduced the risk of acute kidney injury by 23%. The risk of cardiovascular death was also reduced (RR 0.86), but not the risk of non-cardiovascular death (RR 0.94). When looking at safety outcomes, the risk of ketoacidosis in patients with diabetes allocated to SGLT2 inhibitors was higher than those allocated to placebo (RR 2.12). Across all trials, SGLT2 inhibitors were associated with an increased risk of lower limb amputation by 15%, mainly driven by the results of one of the 13 trials included.

RELATED REPORTS

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease

Wellness Check: Exercise

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute kidney injury (AKI)chronic kidney diseasediabetesdiabetes mellituseGFRend-stage renal disease (ESRD)glomerular filtration rate (GFR)heart failurekidney diseaseSGLT-2 inhibitorssglt2 inhibitorstype 2 diabetesType 2 Diabetes Mellitus
Previous Post

Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation

Next Post

#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival

RelatedReports

Intravenous contrast may not increase risk of acute kidney injury
Chronic Disease

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

February 3, 2023
CPAP may not decrease cardiovascular events in sleep apnea
Endocrinology

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease

February 2, 2023
Few older adolescents meet recommended levels of physical activity
Wellness

Wellness Check: Exercise

February 2, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Next Post
#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival

#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

Wellness Check: Spirituality

Preterm birth associated with lower high school academic performance

Third trimester prenatal infections associated with decreased cognitive outcomes in children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options